Exelixis Competitors and Similar CompaniesClear all

Exelixis's competitors and similar companies include Deciphera Pharmaceuticals, NiKang Therapeutics and OBI Pharma.

	Exelixis Exelixis is an oncology company that develops cancer treatments.	Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.	NiKang Therapeutics NiKang Therapeutics is a biotech company focused on developing small molecule oncology medicines.	OBI Pharma OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics.
Founding Date	Founding Date 1994	Founding Date 2003	Founding Date 2017	Founding Date 2002
Type	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Alameda, US HQ	Locations Waltham, US HQ Lawrence, US	Locations Wilmington, US HQ	Locations TW HQ San Diego, US
Employees	Employees 1,3107% increase	Employees 35037% increase	Employees 442% decrease	Employees 124
Valuation ($)	Valuation ($) 8.2 b	Valuation ($) 2.2 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1.8b (FY, 2023)	Revenue (est.) $163.4m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) NT$41.5m (FY, 2023)
Cost of goods	Cost of goods $72.5m (FY, 2023)	Cost of goods $3.7m (FY, 2023)	Cost of goods N/A	Cost of goods NT$115m (FY, 2023)
Gross profit	Gross profit $1.8b (FY, 2023)	Gross profit $159.6m (FY, 2023)	Gross profit N/A	Gross profit (NT$63.8m) (FY, 2023)
Net income	Net income $207.8m (FY, 2023)	Net income ($194.9m) (FY, 2023)	Net income N/A	Net income (NT$1.3b) (FY, 2023)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 714m	Total funding raised $ 200m	Total funding raised N/A